Pontine Glioma - Pipeline Review, H1 2020
|発行||Global Markets Direct||商品コード||361620|
|出版日||ページ情報||英文 469 Pages
|脳幹グリオーマ：パイプライン製品の分析 Pontine Glioma - Pipeline Review, H1 2020|
|出版日: 2020年05月30日||ページ情報: 英文 469 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Pipeline Review, H1 2020, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.
Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 16, 12, 1, 11 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 3, 1 and 1 molecules, respectively.
Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.